Clinical trials: Multiple Sclerosis Subjects
Multiple Sclerosis
Effect of the Vojta Therapy in Patients Multiple Sclerosis
Multiple sclerosis is the most common disabling neurological disease in young adults. Inflammation, demyelination, neurodegeneration, gliosis and repair processes are involved in its process, which are responsible for the…
- Trial name
- NCT05558683
- Testing
- Randomized clinical trial.
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Aymara Abreu Corrales
Relapsing Remitting Multiple Sclerosis
Melatonin in Patients With Multiple Sclerosis (MS).
To date, there are no published data on the role of melatonin supplementation or the appropriate dose for patients with multiple sclerosis.
- Trial name
- NCT03498131
- Testing
- 3 mg Melatonin, 5 mg Melatonin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis, Neurogenic Bladder
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
A clinical study to evaluate the efficacy and safety of solifenacin in patients with bladder symptoms due to spinal cord injury or multiple sclerosis
- Conditions
- Multiple Sclerosis, Neurogenic Bladder, Spinal Cord Diseases
- Trial name
- SONIC (NCT00629642)
- Testing
- Solifenacin Succinate, Oxybutynin Hydrochloride
- Where
- 39 sites in Australia, Belgium and 9 more
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma Inc
Primary Progressive Multiple Sclerosis
A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo
This Phase 2 study is intended to serve as a proof of concept for potential treatment with laquinimod in patients with PPMS. The study is also aimed at evaluating 2 doses of laquinimod in this population.
- Trial name
- ARPEGGIO (NCT02284568)
- Testing
- Laquinimod
- Where
- 99 sites in United States, Canada and 8 more
- Volunteers
- 374 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
Rebif® Rebidose® Versus Rebiject II® Ease-of-Use
This is a Phase 4, prospective, open-label, randomized, cross-over, multicenter trial to evaluate ease-of-use with Rebif® Rebidose® and Rebiject II® autoinjectors in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT02019550
- Testing
- Rebif Rebidose, Rebiject II
- Where
- 21 sites in United States
- Volunteers
- 97 people
- Sponsor
- EMD Serono
Multiple Sclerosis
Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis
This is a study to count the number of white blood cells in the cerebrospinal fluid and blood at the beginning and end of treatment with firategrast and at 4 and 12 weeks after stopping firategrast.
- Trial name
- NCT00469378
- Testing
- firategrast
- Where
- 10 sites in Belgium, Czechia and 3 more
- Volunteers
- 46 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis (ALS)
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using…
- Trial name
- NCT07142291
- Testing
- Cromolyn Sodium (34.2 mg BID), Cromolyn Sodium (17.1 mg BID), Riluzole (100 mg)
- Where
- 22 sites in United States, Czechia and 4 more
- Volunteers
- 105 people
- Sponsor
- PhenoNet, Inc.
Multiple Sclerosis, Relapsing-Remitting
AVONEX® Combination Trial - "ACT"
The purpose of this study is to determine the efficacy and safety of combination therapy with AVONEX plus low dose oral methotrexate (MTX), every other month courses of intravenous methylprednisolone (IVMP), or both in patients…
- Trial name
- NCT00112034
- Testing
- Methotrexate, IV methylprednisolone
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
The purpose of this study is to make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-301 study according to the protocol and to evaluate the long-term safety, tolerability and effect on…
- Trial name
- NCT00988052
- Testing
- Laquinimod
- Where
- 135 sites in United States, Austria and 21 more
- Volunteers
- 839 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Spasticity
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS)…
- Trial name
- NCT01844232
- Testing
- arbaclofen
- Where
- 35 sites in United States, Russia and 1 more
- Volunteers
- 150 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Relapsing Multiple Sclerosis
Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis
The primary objective of this study is to determine the efficacy of peginterferon beta-1a in reducing the annualized relapse rate (ARR) in participants with relapsing multiple sclerosis (RMS) at 1 year.
- Trial name
- ADVANCE (NCT00906399)
- Testing
- BIIB017 (peginterferon beta-1a)
- Where
- 178 sites in United States, Belgium and 24 more
- Volunteers
- 1,516 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
- Trial name
- NCT00882999
- Testing
- LY2127399
- Where
- 63 sites in United States, Bulgaria and 11 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
Multiple Sclerosis
Drug-Drug Interaction of Cladribine and Pantoprazole in Multiple Sclerosis Subjects
The purpose of the study is to assess the influence of pantoprazole on the pharmacokinetic profile of cladribine, especially in terms of extent of absorption of cladribine since pH-modifying drug may potentially affect the…
- Trial name
- NCT00938366
- Testing
- Cladribine, Pantoprazole
- Volunteers
- 18 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Study of Drug-drug Interaction of the Effects of Gemfibrozil and Rifampicin on SAR442168 in Healthy Adult Subjects
This is a Phase 1, single-center, open-label, non-randomized study to assess the effects of CYP2C8 inhibition using gemfibrozil, and CYP3A4 and CYP2C8 induction using rifampicin on the pharmacokinetics of SAR442168 in healthy…
- Trial name
- NCT06064539
- Testing
- Tolebrutinib, gemfibrozil, rifampicin
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis
A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets
The purpose of this study is to explore the concept that biomarker sensitivity will detect activity in Multiple Sclerosis (MS) subjects and allow appropriate change in treatment to prevent dysfunction.
- Trial name
- NCT04550455
- Testing
- Cladribine Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Keith Edwards, M.D.
Multiple Sclerosis
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
The goal of this study was to evaluate the safety, tolerability and effectiveness of oral cladribine when taken in combination with Interferon-beta (IFN-beta) therapy for the treatment of multiple sclerosis (MS).
- Trial name
- ONWARD (NCT00436826)
- Testing
- Cladribine, Interferon-beta (IFN-beta)
- Where
- 39 sites in United States, Italy and 2 more
- Volunteers
- 172 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Multiple Sclerosis
Efficacy and Safety of GTR in Comparison to Copaxone®
The purpose of this study is demonstrate that efficacy and safety of Synthon's glatiramer acetate (GTR) is equivalent to Copaxone® (Teva) in patients with relapsing remitting multiple sclerosis
- Trial name
- GATE (NCT01489254)
- Testing
- Glatiramer Acetate (GTR), Glatiramer Acetate (Copaxone®)
- Where
- 133 sites in United States, Belarus and 17 more
- Volunteers
- 794 people
- Sponsor
- Synthon BV
Alzheimer Disease, Parkinson Disease
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
The underlying goal of this study is to assess [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.
- Conditions
- Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
- Trial name
- PBR06 (NCT01028209)
- Testing
- [18F] PBR06
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis
A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
The primary objective of the study is to estimate the annualized relapse rate (ARR) in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who are treated with dimethyl fumarate (DMF) over a 12-month period.
- Trial name
- PROTEC (NCT01930708)
- Testing
- dimethyl fumarate
- Where
- 90 sites in Austria, Belgium and 9 more
- Volunteers
- 1,114 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis
Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate
This is a study evaluating the effect on brain volume of daily glatiramer acetate (GA) and add-on pulse steroids.
- Trial name
- ASSERT (NCT00203047)
- Testing
- Glatiramer Acetate, Prednisone
- Volunteers
- 414 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.